Analyst Price Targets — TELA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 1, 2025 1:42 pm | Frank Takkinen | Loop Capital Markets | $3.00 | $1.17 | StreetInsider | TELA Bio, Inc. (TELA) PT Lowered to $3 at Lake Street Capital Markets |
| December 1, 2025 1:41 pm | — | Lake Street | $3.00 | $1.24 | TheFly | Tela Bio price target lowered to $3 from $6 at Lake Street |
| November 14, 2025 1:13 pm | — | Piper Sandler | $1.25 | $0.93 | StreetInsider | TELA Bio, Inc. (TELA) PT Lowered to $1.25 at Piper Sandler |
| October 4, 2024 8:46 am | Frank Takkinen | Lake Street | $8.00 | $2.52 | TheFly | Tela Bio's OviTex 'primary beneficiary' of BD settlement, says Lake Street |
| August 13, 2024 6:38 am | Matt O'Brien | Piper Sandler | $8.00 | $4.01 | TheFly | Tela Bio price target lowered to $8 from $10 at Piper Sandler |
| May 22, 2024 6:24 am | Kyle Rose | Canaccord Genuity | $14.00 | $6.20 | StreetInsider | Canaccord Genuity Reiterates Buy Rating on TELA Bio, Inc. (TELA) |
| May 10, 2024 8:21 am | Matt O'Brien | Piper Sandler | $10.00 | $5.78 | StreetInsider | TELA Bio, Inc. (TELA) PT Lowered to $10 at Piper Sandler |
| November 10, 2022 9:57 am | — | JMP Securities | $20.00 | $8.10 | Benzinga | JMP Securities Maintains Market Outperform on TELA Bio, Lowers Price Target to $20 |
| November 9, 2022 9:09 pm | Matt O'Brien | Piper Sandler | $15.00 | $6.50 | TheFly | Tela Bio price target lowered to $15 from $20 at Piper Sandler |
Latest News for TELA
Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program
TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.22 per share a year ago.
MALVERN, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Board of Directors of TELA Bio approved inducement grants of stock options to purchase an aggregate of 2,370,000 shares of its common stock and restricted stock units covering 500,000…
MALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced that the Board of Directors (the “Board”) has appointed Heather Getz as Chief Executive Officer and Director, effective today.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TELA.
U.S. House Trading
No House trades found for TELA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.